DCVC

Activity from announced rounds

Activity in this selectionOct 27, 2026 · Jul 30, 2026

DCVC is an investment firm identified by TypeSafe AI as an existing investor and by its own communications as a backer of Shennon Biotechnologies.

Recorded funding activity

TypeSafe turns unstructured inputs into typed decisions and probability scores for automated software. Shennon develops T-cell engager therapies for solid tumors. Separate TypeSafe financings remain separate events under one investor history.

Sources
Rounds participated in
7
Confirmed lead rounds
3
1 roles undisclosed
New companies
6
First participation on record · 1 follow-on
Funding in participating rounds
$1.1B
6 disclosed · full round size, not this investor’s share

By stage

Seed3
Series A2
Series B1
Undisclosed1

By primary sector

AI3
Biotech1
Climate tech1
Hardware1
Healthtech1

By country

United States5
United Kingdom2

Rounds

7 in this selection
BioStack

BioStack builds clinical data pipelines and realistic training environments for healthcare and drug-discovery AI.

$9.5MSeed
Lead
TypeSafe AI

Developer infrastructure that turns unstructured inputs into typed decisions and probability scores for automated software workflows.

$870MSeries A
Participant
Universal Quantum

Modular trapped-ion quantum computers built by connecting small quantum chips.

>$100MSeries A
Lead
Rainmaker

Rainmaker develops cloud-seeding technology and atmospheric research tools to increase freshwater supply.

$100MSeries B
Participant
TypeSafe AI

Developer infrastructure that turns unstructured inputs into typed decisions and probability scores for automated software workflows.

$40MSeed
Lead
Shennon Biotechnologies

Shennon Biotechnologies is developing precision T-cell engager immunotherapies for solid tumors.

$12MFunding
Participant
Callosum

Software infrastructure allowing AI workloads to run across different chips and models

$100MSeed
Role not disclosed